Myelodysplastic syndromes (MDS) are clonal malignant stem cell disorders characterized by inefficient hematopoiesis. The role of the marrow microenvironment in the pathogenesis of the disease has been controversial and no study has been performed so far to characterize mesenchymal cells (MC) from MDS patients and to analyse their ability to support hematopoiesis. To this end, we have isolated and characterized MC at diagnostic marrow samples (n ¼ 12) and have purified their CD34 þ CD38À and CD34 þ CD38 þ counterparts (n ¼ 7) before using MC as a short-and long-term hematopoietic support. We show that MC can be readily isolated from MDS marrow and exhibit a major expansion potential as well as an intact osteoblastic differentiation ability. They do not harbor the abnormal marker identified by FISH in the hematopoietic cells and they stimulate the growth of autologous clonogenic cells. Conversely, highly purified stem cells and their cytokine-expanded progeny harbor the clonal marker with variable frequencies, and both normal and abnormal long-term culture-initiating cell-derived progeny can be effectively supported by autologous MC. Thus, we demonstrate that MDS marrow is an abundant source of MC appearing both cytogenetically and functionally noninvolved by the malignant process and able to support hematopoiesis, suggesting their possible usefulness in future cell therapy approaches.
Myelodysplastic syndromes (MDS) are clonal malignant stem cell disorders characterized by inefficient hematopoiesis. The role of the marrow microenvironment in the pathogenesis of the disease has been controversial and no study has been performed so far to characterize mesenchymal cells (MC) from MDS patients and to analyse their ability to support hematopoiesis. To this end, we have isolated and characterized MC at diagnostic marrow samples (n ¼ 12) and have purified their CD34 þ CD38À and CD34 þ CD38 þ counterparts (n ¼ 7) before using MC as a short-and long-term hematopoietic support. We show that MC can be readily isolated from MDS marrow and exhibit a major expansion potential as well as an intact osteoblastic differentiation ability. They do not harbor the abnormal marker identified by FISH in the hematopoietic cells and they stimulate the growth of autologous clonogenic cells. Conversely, highly purified stem cells and their cytokine-expanded progeny harbor the clonal marker with variable frequencies, and both normal and abnormal long-term culture-initiating cell-derived progeny can be effectively supported by autologous MC. Thus, we demonstrate that MDS marrow is an abundant source of MC appearing both cytogenetically and functionally noninvolved by the malignant process and able to support hematopoiesis, suggesting their possible usefulness in future cell therapy approaches.
Introduction
Myelodysplastic syndromes (MDS) represent a group of hematological malignancies characterized by a clonal expansion of a malignant stem cell with a predisposition to apoptosis leading to an inefficient hematopoiesis (Heaney and Golde, 1999) . MDS are also characterized by their heterogeneity, in terms of prognosis, cytogenetic abnormalities and progression toward a leukemic phase. The FAB classification based on the cytological features (Bennett et al., 1982) more recently completed by IPSS score (Greenberg et al., 1997) allows the estimation of a leukemic progression in patients with MDS. Cytogenetic abnormalities are recognized in a large majority of patients, either primary or secondary MDS representing, in this last category, about 80% of cases (Kantarjian et al., 1986) . Among the most consistent cytogenetic abnormalities, partial or total losses of chromosomes 5 or 7 as well as trisomies of chromosomes 8 and 13 and translocations such as t(6;9) are well recognized (Mauritzson et al., 1999) .
From the practical point of view, the aggressive treatment in MDS in the absence of an allogeneic donor includes combination or single chemotherapy, which did not show any benefits as compared with supportive measures (Heaney and Golde, 1999) . The ability to perform autologous transplants might improve response rates (De Witte et al., 1997; Wattel et al., 1999) but the major problem remains the low numbers of stem cells obtained after induction of remission and their clonal contamination by malignant MDS stem cells.
Thus, it is of crucial importance to characterize the stem cells involved in the pathogenesis of MDS and to generate approaches to amplify normal cells for autografting purposes. Recently, mesenchymal cells (MC) have been shown to have a significant benefit in supporting hematopoiesis either in preclinical (Prockop, 1997; Deans and Moseley, 2000) or clinical settings (Horwitz et al., 1999; Koc et al., 2000) . MC represent a rare population of stem cells present in the bone marrow with a major proliferative (Colter et al., 2000) and differentiative ability, in particular to generate chondrocytes, osteoblasts and muscle cells (Kadiyala et al., 1997) . In this study, we show that MC can be obtained with high efficiency from patients with MDS at diagnosis. These cells are devoid of cytogenetic abnormalities identified by FISH in the hematopoietic cells and more importantly allow stimulation of hematopoietic stem cells with short-and long-term potential. These findings suggest that autologous MC could be a source of stem cell support in future cell therapy applications in MDS. Table 1 shows the characteristics of the 12 patients included in the study. Six patients presented with a refractory anemia with excess of blasts (RAEB) or refractory anemia with excess of blasts in transformation (RAEB-T), and 8/12 had cytogenetic abnormalities identified by FISH.
Results

Patient characteristics
MC cultures and amplification potential
MC were obtained with high efficiency from all patients. After the initial plating in liquid cultures, these cells appeared as small refringent foci after 2 weeks. They were then trypsinized and cultured in DMEM 20% FCS for expansion. In order to determine their expansion potential, they were cultured in two conditions: first, they were plated at 1.5, 3, 6 and 10 cells/cm 2 for 2 weeks and the adherent foci were counted after staining. Figure 1 shows the number of foci obtained in these conditions from two MDS patients and two normal marrow donors. As can be seen in this figure, the number of foci generated by MDS-MC was not significantly different from that obtained from normal marrow donors. In order to determine the expansion potential of the cells, previously frozen MC (passages 8-10) from two MDS patients were cultured at low densities (12 cells/cm 2 ) for 2 weeks and the cell numbers obtained were compared to those obtained with normal marrow MC by counting the absolute numbers of MC obtained in these cultures at day þ 14. MDS-MC exhibited mean 324-fold expansion for patient UPN2 (n ¼ 3) and a mean 479-fold for patient UPN6 (n ¼ 3). These values were comparable to those obtained with MC from two normal marrow donors. MC were then analysed using cell surface markers in all patients. In all patients, the MC appeared to be consistently negative for CD34, CD45, CD117 (c-kit) and CD31. They were found to be very strongly positive for CD105 (endoglin) marker, whereas they were variably positive for CD29 and CD44 antigen. In order to determine if the MC that we have isolated from MDS patients had an intact differentiation ability, we have cultured the cells under the conditions of osteoblastic differentiation. After 14 days, the cells were evaluated by using von Kossa staining and alkaline phosphatase assays. These assays The same results were also obtained in two other patients using MLL (UPN3) and centromeric chromosome 7 (UPN8) probes, respectively (Table 2) . Thus, MC purified and expanded from patients with MDS do not exhibit clonal chromosomal abnormalities detectable by FISH in their hematopoietic counterparts.
MC support short-term hematopoiesis in patients with MDS with stimulation of both normal and malignant hematopoiesis
We then wanted to determine if the MC obtained from MDS patients would be able to support short-term hematopoiesis. For this purpose, we have designed a simple coculture technique consisting of the clonogenic assay of marrow progenitors obtained at diagnosis of MDS. A total of 5 Â 10 4 marrow MNC were plated in the presence or in the absence of 2 Â 10 3 autologous MC. The numbers of progenitors obtained in the absence (control dishes) or in the presence of MC were evaluated at days 10 and 21.
As can be seen in Figure 3 , in six out of seven patients, there was an increase in the numbers of colony-forming unit-cells (CFU-C), when the marrow cells were cultured in the presence of MC with evidence of a dissociated response: an increase of colony-forming unit granulocyte macrophage (CFU-GM) numbers was documented in four patients, whereas burst-forming unit-erythroid (BFU-E) numbers were found to be increased in two patients (UPN2 and UPN5). The CFU-GM numbers were about twofold higher in three patients (UPN4, UPN6, UPN7) and nine-fold higher in UPN3, with a mean absolute number of CFU-GM of 55 (range 6-164) in the absence of MC and a mean absolute number of 111 (range 41-295) in the presence of MC coculture. Interestingly, in two patients, despite the fact that the numbers of total BFU-Es increased only twice in the presence of the coculture, the qualitative composition of the BFU-Es was different, with evidence of a dramatic increase in the numbers of primitive BFU-Es containing up to 32 clusters, suggesting the stimulation of primitive erythroid precursors by MC (Figure 4 ). These findings were reproducible in these two patients in several experiments. Given the fact that these progenitors were obtained from the patients at diagnosis, it was interesting to determine whether the hematopoietic stimulation included only the neoplastic clone or the residual normal cells, not expressing the studied marker. Individual progenitors were therefore plucked from methycellulose cultures generated in the presence or in the absence of MC, pooled 5 by 5 and analysed using FISH. This analysis performed in two informative patients is summarized in Table 3 . In UPN7, the percentage of abnormal nuclei ( þ 8) in progenitors cultured in the absence or in the presence of MC was similar (91 and 92%, respectively, n ¼ 200 nuclei analysed). Importantly, in a second patient (UPN3) whose clonogenic progenitors appeared to have residual normal nuclei (39% of nuclei positive for del(MLL) marker, n ¼ 200 nuclei counted), the coculture with MC induced a ninefold increase in the numbers of CFU-GM with no detectable del(MLL) nuclei (n ¼ 200 nuclei counted). These results suggest that coculture of hematopoietic progenitors in MDS patients stimulates both normal and malignant cells.
MC from MDS patients support both normal and leukemic long-term hematopoiesis originating from highly purified stem cell populations In order to determine whether autologous MC would support the LTC-IC-derived progeny, we have performed long-term cultures in the presence of either the murine MS-5 cell layer or the autologous MC from patients with MDS. Long-term cultures have been established according to previously published procedures (Tourino et al., 2001) . LTC assays were started using primitive hematopoietic cell populations purified on the basis of the expression of CD34 and CD38 antigens. CD34 þ CD38À and CD34 þ CD38 þ cell populations were sorted by FACS. Due to the low numbers of purified stem cell populations, direct FISH analysis of FACS-sorted fractions was possible only in two patients. To perform this analysis in all patients, and to analyse the response of primitive cells to growth factors, we have expanded FACS-sorted CD34 þ CD38À and CD34 þ CD38 þ cell populations in the presence of combination of six cytokines, followed by FISH analysis of expanded cells in serum-free conditions. Cytokine-expanded cells were then assayed for their LTC-IC contents in the presence of either autologous MC or murine MS-5 stroma. Results indicate the fold increase of CFU-GM and BFU-E in the presence of MC as compared with total CFU-C count without MC Figure 4 Major increase of primitive BFU-E using coculture in the presence of low numbers of autologous MC in UPN2 and UPN5. Although quantitatively the total numbers of BFU-E are increased by only twofold (see Figure 3) , the numbers of primitive BFU-E up to 32 clusters are dramatically higher when autologous MC are present in methylcellulose cultures Figure 5 shows the proliferative response of the CD34 þ CD38À and CD34 þ CD38 þ cell populations expanded for 13 days in the presence of IL-3, SCF, rhMGDF, l-Flt3, GM-CSF and IL-6. A significant expansion of nucleated cells was obtained in three patients with a diagnosis of refractory anemia (RA) in the CD34 þ CD38-(UPN6, UPN7 and UPN10) and in the CD34 þ CD38 þ (UPN6 and UPN10) fractions. No proliferative response could be obtained in one patient with RA (UPN3) and one patient with RAEB (UPN9) ( Figure 5 ). As can be seen in Table 4 , FISH analysis was performed in seven patients in the CD34 þ CD38 þ /À cell populations after expansion. In two patients, the single CD38 marker allowed the identification of a cell population with no FISH-detectable cytogenetic abnormality, as the progeny of CD34 þ CD38-cells amplified by cytokines for 13 days were consistently negative (UPN6 and UPN11). The CD34 þ CD38 þ cell populations were more uniformly involved almost in all patients, with the percentages of FISH-positive nuclei varying between 89 and 97% (Table 4) .
We next wished to determine the LTC-IC-generating potential of both CD34 þ CD38À and CD38 þ fractions, in the presence of autologous MC layers as compared with standard murine MS-5 cell layers. Due to the low numbers of cells available in these experiments, the LTC assays were started using cytokineexpanded CD34 þ CD38À or CD34 þ CD38 þ cell populations. After 5 weeks, LTC-IC-derived hematopoietic progeny (pooled CFU-GM from methylcellulose cultures in UPN6 and nonadherent fractions of LTC in UPN3 and UPN7) were analysed by FISH. Table 5 shows the comparative analysis of LTC-IC-derived activity originating from both fractions and demonstrates the ability of MC to support the growth of primitive MDS cells despite the previous 13-day amplification in the presence of cytokines in at least three patients (Table 5) . Table 6 summarizes the results of the cytogenetic analysis on the LTC-IC-derived progeny. As previously seen in Table 4 , the UPN3 sample analysed after the expansion of CD34 þ CD38 þ fraction contained 90% of nuclei with del(MLL), with only a small percentage of nuclei appearing normal. When this sample was tested in LTC-IC assays, in the presence of either MS5 or autologous MC, there was a considerable enrichment in normal progenitors: only 32 and 17% of the nuclei appeared with del(MLL), after long-term culture in the presence of MS-5 or MC, respectively (Table 5 ). This considerable enrichment in normal cells was not found in UPN7 in which cytokine-expanded CD38 þ cells or their LTC-derived progeny remained largely contaminated with >90% of nuclei exhibiting trisomy 8 (Tables  4 and 5 ). On the other hand, in patient UPN6, the CD34 þ CD38À fraction, which was found to be negative on þ 8 marker after expansion of the cells (Table 4) , was found to give rise exclusively to normal LTC-IC derived progeny either in the presence of MS-5 or in the presence of MC layers.
Discussion
MC derive from mesenchymal stem cells present in the bone marrow and have the ability to differentiate into osteoblasts, chondrocytes and adipocytes in well-defined conditions (Deans and Moseley, 2000) . They have recently been the subject of an intense investigative work for the purposes of cell therapy either for the tissue repair or as a hematopoietic support, in children by osteogenesis imperfecta (Horwitz et al., 1999) or in breast cancer patients receiving intensive chemotherapy, with the goal of reducing bone fractures in the first case and reducing chemotherapy-related cytopenias in the latter (Koc et al., 2000) . MC have also been shown to stimulate the hematopoietic engraftment of primitive human stem cells transplanted into immunodeficient mice (Angelopoulou et al., 2003; in 't Anker et al., 2003; Bensidhoum et al., 2004) , suggesting that they could facilitate the correct homing of stem cells toward hematopoietic niches, although the relevance of this concept for in vivo hematopoiesis remains to be proven.
MDS represent a prototype of the clonal malignancy with an inefficient hematopoiesis. Hematopoietic cell therapy approaches in MDS require careful consideration of the clonal involvement of stem cell populations and responses of the MDS stem cells to different growth factor combinations. In the absence of the possibility of performing an allogeneic stem cell transplantation, which is the only curative approach (Nevill et al., 1998; Guardiola et al., 2002) , autologous transplants have demonstrated a significant benefit as compared with standard chemotherapy regimens in patients with MDS (De Witte et al., 1997) . However, this approach can be complicated by the fact that recovery from aplastic period is slow and that the graft might be contaminated by malignant stem cells (De Witte et al., 1997) . The ability to mobilize in the peripheral blood polyclonal cells after intensive chemotherapy demonstrates that significant numbers of nonclonal stem cells persist in the MDS marrow (Delforge et al, 1998) . The role of stromal cells in the pathophysiology of the inefficient hematopoiesis observed in MDS patients has been the subject of a long-standing debate (Deeg, 2002) . Although the hematopoietic output after long-term culture of MDS marrow cells was found to exhibit patient-dependent variations, globally, MDS stroma has been shown to be able to support the growth of normal hematopoietic cells in long-term cultures, suggesting no intrinsic functional defect (Coutinho et al., 1990) . These findings were confirmed by other works (Deeg et al., 2000) showing that stromal layers derived from MDS marrow had normal or even increased capacity to sustain the growth of both MDS and normal hematopoietic progenitors. Other studies suggested, however, that MDS stromal layers were inefficient in their hematopoietic supporting capacity (Aizawa et al., 1999) .
To our knowledge, our study is the first to document the hematopoietic supporting ability of MC obtained from patients with MDS. We demonstrate that MC can be easily purified from the bone marrow of MDS patients at diagnosis and these cells exhibit no significant differences as compared with MC obtained from normal donors with regard to their growth and phenotype, and they exhibit even higher expansion characteristics. When seeded at very low densities, they give rise to macroscopically visible colonies, which are consistently larger in size as compared with controls. Also, we report that they do not harbor the abnormal marker of the clone identified by FISH in the hematopoietic cells of the same patients. In all patients that we have tested, the clonal marker was readily identified in hematopoietic cells (marrow metaphases or in CD34 þ cell populations), whereas all MC analysed appeared to be normal ( Figure 2 and Table 2 ). MDS-MC seemed to be functionally efficient as they have been found to stimulate the growth of clonogenic hematopoietic progenitors (Figure 3) and to support the growth of LTC-IC progeny (Table 5) . In two patients, we also observed a major increase of primitive BFU-E production when marrow cells were cocultured with autologous MC (Figure 4) , suggesting that adequate microenvironmental conditions can allow circumvention of the inefficient hematopoiesis in selected MDS patients.
The use of cytogenetic markers and X-linked clonality analyses have revealed, in recent years, the considerable heterogeneity of MDS with regard to the initial target stem cell (Soenen et al., 1995; Saitoh et al., 1998; Nilsson et al., 2000) . Few data are available with regard to the analysis of CD34 þ CD38-cell populations. A study performed by Nilsson et al. (2000) showed that CD34 þ CD38À cell populations could frequently harbor the abnormal cytogenetic markers in patients with 5qÀ syndromes, whereas other studies analysing more mature cell compartments suggested that the initial target cell for MDS clone was a more mature stem cell (Saitoh et al., 1998) . In acute myeloid leukemia, the existence of a hierarchical involvement of stem cells has been demonstrated with evidence of a target leukemiainitiating cell in the CD34 þ CD38-cell population (Bonnet and Dick, 1997) except for the subgroup of acute promyelocytic leukemia (Turhan et al., 1995) . In (Thanopoulou et al., 2004) . Our study suggests that in some patients, CD38 antigen is a distinctive marker to efficiently purify a normal CD34 þ CD38-stem cell population in cytokineexpanded cells (UPN6 and UPN11) (Table 4 ) and in their LTC-IC-derived progeny (UPN6 ; Table 5 ), whereas CD34 þ CD38 þ cells consistently carried the abnormal clonal marker detectable by FISH. These data suggest, therefore, a heterogeneity of the target MDS stem cell population, which will require further analysis. Our data establish, however, the possibility to identify non-neoplastic cells in some patients even at diagnosis with the ability of these cells to amplify in response to growth factors and the ability of autologous MC to sustain their LTC-IC potential.
The latter finding could be of interest for cell therapy purposes as these cells could be used in combination with autografting strategies to augment the size of an autograft in remission. The ability to detect hematopoiesis with no chromosomal markers at diagnosis of the disease underscores the possibility of enriching considerably an autograft by the use of an MC-based expansion strategy at remission. The feasibility of this approach requires further study by the use of clinically applicable MC culture strategies and coculture techniques in MDS patients in cytogenetic remission. These approaches could be a useful intensification strategy in MDS, in which autografting has shown evidence of clinical benefit (De Witte et al., 1997).
Materials and methods
Cells
Marrow samples from patients with MDS at diagnosis have been obtained with informed consent of the patients. Patients with cytogenetic abnormalities have been included in the study, and afterwards only those with cytogenetic abnormalities identified by FISH were analysed. Marrow cells were separated using Ficoll-Hypaque gradients and mononuclear cell (MNC) fractions were used for the isolation of MC. The same cells were also used for clonogenic assays as well as for cell purification purposes by cell sorting.
MC isolation
MC were isolated using the adhesion protocol developed by Colter et al. (2000) . Briefly, low-density MNC isolated from bone marrow were cultured at the density of 10 6 cells/ml for 18 h in DMEM medium containing 20% FCS. Nonadherent cells were then discarded, the dish was washed twice and the remaining cells were cultured with twice-weekly total medium changes for 2 weeks until the appearance of adherent cells. These cells were trypsinized, and then amplified in DMEM medium at low density (12 cells/cm 2 ) with 20% FCS. After obtaining semiconfluent cultures, the cells were passaged 1-2 times/week by seeding 2 Â 10 5 cells/75 cm 2 flasks.
FACS analysis
The characterization of MC was performed by the use of the cell markers CD34, CD45, CD117, CD29 and CD105, purchased from Beckton-Dickinson, at dilutions recommended by the manufacturer.
Differentiation assays
To induce osteoblastic differentiation, MC were cultured in the presence of b-glycerophosphate (10 mM), dexamethasone (10 À7 M) and ascorbic acid (0.2 mM) for 14 days. Cells were then evaluated for osteoblastic differentiation using von Kossa staining and alkaline phosphatase assays.
von Kossa staining
Adherent cells were fixed with methanol at À201C for 2 min, treated with 2% silver nitrate (Sigma) and placed under a UV lamp for 1 h. After being rinsed in dH 2 O, slides were fixed with 2.5% sodium thiosulfate (Sigma) for 5 min and then washed. They were then counterstained with 1% neutral red (Sigma) for 1 min and rinsed in tap water.
Alkaline phosphatase staining
Adherent MC were fixed in methanol for 2 min, and washed for 10 min in 100 mM Tris-HCl pH 9.5, 100 mM NaCl and 10 mM MgCl 2 . Cells were then stained with 5-bromo-4-chloro-3-indolyl phosphate (BCIP) for 5-10 min. They were then rinsed in water, dried and analysed under an inverted microscope.
Clonogenic assays
These tests were performed using standard methycellulose cultures (Stem Cell Technologies). Hematopoietic colonies obtained were counted at day 14 and individual colonies were plucked and pooled and cytospins were performed for FISH analysis.
Short-term cultures in the presence of MC
To determine the ability of MC to stimulate hematopoiesis in vitro, a short-term culture technique was devised. Ficolled MNC cells obtained from the marrow at diagnosis were thawed and 5 Â 10 4 viable cells were cultured in methycellulose in the absence or presence of a small number (2 Â 10 3 ) of autologous MC, which had been mixed with hematopoietic cells. The MC were previously expanded and frozen from each patient sample. The dishes were then counted at day 14, and the number and the aspects of colonies generated in the presence or absence of MC were compared.
Cell sorting
Marrow cells obtained at diagnosis were purified using FACSVantage (Becton Dickinson, San Jose, CA, USA) after labeling with anti-CD34 and anti-CD38 antibodies in the presence of appropriate controls. CD34 þ CD38À and CD34 þ CD38 þ cell populations were sorted and used for either FISH analyses or started in long-term culture assays with half-medium changes for 5 weeks. To compare the efficiency of MC to support long-term hematopoiesis, we have performed the longterm culture-initiating cell (LTC-IC) assays either in the presence of the standard MS-5 murine stromal layer or in the presence of autologous or allogeneic MC. At the end of the period of 5 weeks, adherent and nonadherent cells were harvested and assayed in methylcellulose in order to determine Characterization of MC from MDS patients V Soenen-Cornu et al the progeny of LTC-IC arising in the presence or in the absence of MC. The individual colonies were then plucked and pooled and FISH analysis was performed in order to determine the presence or the absence of the clonal cytogenetic abnormality in the progeny of LTC-IC.
Expansion in the presence of cytokines CD34 þ cells as well as their CD38À and CD38 þ subsets (10 000-50 000 cells according to the number of cells sorted) were cultured in X-Vivo 20 cell culture medium containing six cytokines, including IL-3 (200 U/ml), SCF(50 ng/ml), MGDF (50 ng/ml), l-Flt3 (100 ng/ml), GM-CSF (10 ng/ml) and rhIL-6 (50 ng/ml) in serum-free conditions in the presence of 10% human albumin. These cells were then used either for FISH analyses or for the long-term culture assays in the presence of MC or MS-5 cell layers.
FISH analysis
Interphase nuclei were hybridized with fluorescent labeled probes following CEP7, CEP8, LSI CSF1R (5q33-q34)/ D5S721, D5S23 Dual Color, LSI MLL Dual Color, LSI p53 (17p13.1) and LSI D20S108 (20q12) (Vysis, Downer Grove, IL, USA) according to the manufacturer's recommendations. Between 100 and 500 nuclei were analysed by two different observers. The results were interpreted with regard to the previously established threshold of sensitivity (corresponding to mean values obtained in controls þ 3 s.d.) (data not shown).
